“We must not forget that all patients who acquire a CRBSI were already receiving treatment for one or more other conditions, which is why they had the VAD in place.” Gabriel et al (2014).
Gabriel, J., Hitchcock, J., Hodson, J., Masterton, R.G., Nicholls, M., Franklin, N. and Whitton, J. (2014) Catheter-related bloodstream infections: cost-effective strategies for prevention. British Journal of Nursing. 23(13), Supplement, p.S3-S22.
Most patients admitted to hospital will be the recipient of a peripheral vascular access device (VAD) or, to a much lesser extent, a central venous access device (CVAD), inserted to facilitate their treatment. A catheter-related bloodstream infection (CRBSI) is a potentially preventable complication of any VAD. In 2011, the most recent year for which data are available, the Health Protection Agency (HPA) estimated that 64% of all bloodstream infections occurred in patients who had a VAD in situ (HPA, 2011). The cost to the NHS of managing such infections is estimated to be in the region of £1 billion per annum (Plowman et al, 1999; HPA, 2011). This is in addition to the personal cost endured by each affected individual. We must not forget that all patients who acquire a CRBSI were already receiving treatment for one or more other conditions, which is why they had the VAD in place.
Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).
- Guide for intravenous chemotherapy and associated vascular access devices from Macmillan.
- CancerUK IV chemotherapy information.